Cargando…

Translocation t(3;12)(q26;q21) in JAK2(V617F) Point Mutation Negative Chronic Idiopathic Myelofibrosis: A Case Report

The myeloproliferative diseases (MPDs) or myelo-proliferative neoplasms (MPNs) are a group of diseases of the bone marrow in which excess cells are produced. Chronic idiopathic myelofibrosis (CIMF) is a stem cell defect characterized by splenomegaly with multiorgan extramedullary hematopoiesis, imma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mešanović, S., Šahović, H., Perić, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Macedonian Science of Sciences and Arts 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4347479/ https://www.ncbi.nlm.nih.gov/pubmed/25741217 http://dx.doi.org/10.2478/bjmg-2014-0026

Ejemplares similares

A Case of Type 2 Diabetes Mellitus With t(6;7)(q24;q31.2) Balanced Translocation
por: Cho, Chiharu, et al.
Publicado: (2022)

JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2013)

Molecular characterization of the rare translocation t(3;10)(q26;q21) in an acute myeloid leukemia patient
por: Jancuskova, Tereza, et al.
Publicado: (2014)

A novel insertion ins(18;5)(q21.1;q31.2q35.1) in acute myeloid leukemia associated with microdeletions at 5q31.2, 5q35.1q35.2 and 18q12.3q21.1 detected by oligobased array comparative genomic hybridization
por: Kjeldsen, Eigil
Publicado: (2014)

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
por: Yönal, İpek, et al.
Publicado: (2016)

Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis
por: Nakaya, Y, et al.
Publicado: (2014)

Inhibition of Osteoblast Differentiation by JAK2(V617F) Megakaryocytes Derived From Male Mice With Primary Myelofibrosis
por: Karagianni, Aikaterini, et al.
Publicado: (2022)

Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice
por: Akada, Hajime, et al.
Publicado: (2014)

A novel t(3;12)(q21;p13) translocation in a patient with accelerated chronic myeloid leukemia after imatinib and nilotinib therapy
por: Bennour, Ayda, et al.
Publicado: (2013)

Clinical and Genomic Profiles of Korean Patients with MECOM Rearrangement and the t(3;21)(q26.2;q22.1) Translocation
por: Lee, Jikyo, et al.
Publicado: (2022)

Co‐occurrence of JAK2 V617F‐mutated essential thrombocythemia and chronic lymphocytic leukemia harboring der(8;17)(q10;q10)
por: Manabe, Masahiro, et al.
Publicado: (2022)

Immunoproteasome Genes Are Modulated in CD34(+) JAK2(V617F) Mutated Cells from Primary Myelofibrosis Patients
por: Di Rosa, Michelino, et al.
Publicado: (2020)

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
por: Rai, Shivam, et al.
Publicado: (2022)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
por: Barbui, Tiziano, et al.
Publicado: (2022)

JAK2 Exon 14 Skipping in Patients with Primary Myelofibrosis: A Minor Splice Variant Modulated by the JAK2-V617F Allele Burden
por: Catarsi, Paolo, et al.
Publicado: (2015)

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2023)

Janus Kinase V617F Mutation Detection in Patients with Myelofibrosis
por: Nikolova, D, et al.
Publicado: (2019)

JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis
por: Choi, Michael Y., et al.
Publicado: (2018)

Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice
por: Ozono, Yoshinori, et al.
Publicado: (2020)

Dermatoglyphics and Reproductive Risk in a Family with Robertsonian Translocation 14q;21q
por: Kolgeci, Selim, et al.
Publicado: (2015)

A case of myelodysplastic syndrome with t(10;18)(q26;q21)
por: Ohba, Yusuke, et al.
Publicado: (2019)

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
por: Tefferi, A, et al.
Publicado: (2012)

Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
por: Tognon, Raquel, et al.
Publicado: (2012)

Characterization of Glycoproteoforms of Integrins α2 and β1 in Megakaryocytes in the Occurrence of JAK2V617F Mutation-Induced Primary Myelofibrosis
por: Gaye, Maissa M., et al.
Publicado: (2022)

Expression profiles analysis identifies specific interferon-stimulated signatures as potential diagnostic and predictive indicators of JAK2V617F (+) myelofibrosis
por: Zhao, Yanhong, et al.
Publicado: (2022)

Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation
por: Lee, Jong-Mi, et al.
Publicado: (2023)

A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs
por: Link-Lenczowska, Dorota, et al.
Publicado: (2018)

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022)

Infantile spasms related to a 5q31.2-q31.3 microdeletion including PURA
por: Shimojima, Keiko, et al.
Publicado: (2018)

MYB deregulation from a EWSR1-MYB fusion at leukemic evolution of a JAK2(V617F) positive primary myelofibrosis
por: Pierini, Tiziana, et al.
Publicado: (2016)

Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib
por: Yi, Jun Ho, et al.
Publicado: (2019)

Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy
por: Musto, Pellegrino, et al.
Publicado: (2014)

A novel unbalanced de novo translocation der(5)t(4;5)(q26;q21.1) in adult T-cell precursor lymphoblastic leukemia
por: Kjeldsen, Eigil, et al.
Publicado: (2012)

The JAK2 V617F mutation in isolated neutropenia
por: Langabeer, Stephen E.
Publicado: (2018)

Breakpoint analysis of the recurrent constitutional t(8;22)(q24.13;q11.21) translocation
por: Mishra, Divya, et al.
Publicado: (2014)

伴t(3;21)(q26;q22)髓系肿瘤临床分析
Publicado: (2019)

Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation
por: Langabeer, Stephen E., et al.
Publicado: (2015)

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression
por: Malara, Alessandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qfga7msntkb12ek0r4ejd4b8f0